The Hypothalamic Amenorrhea Podcast · Dani Sheriff

BONUS: Future wave of HA with GLP-1 and HRT

September 18, 2025·48 min·3 clips

A cited research paper states ovulation induction in the face of HA-related elevated cortisol and low T3/T4 is associated with pre-term labor, autism spectrum disorder, and cardiovascular disease in offspring — and 'available data suggests reason for concern.'

1. The Hypothalamic Amenorrhea Podcast hosts Dani and Ashley record a bonus episode during HA Practitioner open enrollment week to discuss what they call 'the future wave of HA' driven by GLP-1 drugs and HRT. 2. Dani is the primary host; Ashley is her co-host and fellow practitioner at the HA Society; neither claims to be a licensed physician or endocrinologist, and both repeatedly disclaim dogmatic positions throughout. 3. The episode's thesis is that two trends — widespread GLP-1 drug adoption and the HRT resurgence — will significantly increase the number of women developing hypothalamic amenorrhea in the coming years. 4. Dani describes already having two clients who lost their menstrual cycles after GLP-1 use, noting one recovered in the same timeframe as a standard HA client, though she cautions the sample is too small to draw conclusions about long-term effects. 5. Ashley explains the mechanism: GLP-1 drugs suppress hunger, causing people to eat less over time, which creates the same chronic caloric deficit that drives HA regardless of whether the deficit originates from willful restriction or pharmacological hunger suppression. 6. Dani raises a concern that GLP-1-driven HA may look different from conventional HA during weight regain in recovery, though she acknowledges there are too few case studies yet to characterize the difference. 7. Ashley describes GLP-1 advertisements as escalating from general weight-loss marketing to postpartum targeting, using 'bloating' as a socially acceptable substitute for the now-criticized 'bounce back' framing. 8. A Serena Williams GLP-1 advertisement is discussed in detail: Williams says 'after I had my kids, my body just didn't feel the same,' and the product website uses the tagline 'Serena's on it, so are you next?' — language the hosts note is transparent about its aspirational intent. 9. Dani questions whether Williams's body, which she describes as 'jacked' in tennis photos, could have sustained elite athletic performance at the lower weight shown in post-retirement images, framing weight loss as a potential trade-off against performance capacity. 10. Ashley reads a direct quote from a research paper stating that the consequences of ovulation induction in the context of HA-associated elevated cortisol, low T3 and T4, and other neuroendocrine changes 'have yet to be determined' but that 'available data suggests reason for concern,' with listed risks including pre-term labor, autism spectrum disorder, cardiovascular disease, and congenital heart defects. 11. The hosts note they are not opposed to IVF or ovulation induction categorically but argue that the question of downstream consequences of forcing ovulation in a metabolically stressed body should be openly discussable. 12. Ashley transitions to the HRT topic, noting that bioidentical hormone replacement therapy is having a cultural resurgence after the reanalysis of older research that previously overstated estrogen's cancer risk. 13. She describes observing a pattern: weight-loss and fitness influencers who describe symptoms consistent with HA — absent cycles, tanked hormones — but attribute them to early or perimenopause rather than low energy availability, and are subsequently placed on HRT. 14. Ashley frames this as a commercial loop: practitioners promote extreme leanness, the resulting hormone loss is diagnosed as menopause, and the depleted hormones are sold back to the patient through HRT — 'what was available for free 99.' 15. She expresses the strongest opposition to hormone pellets specifically, calling them 'mega-dosed hormones under the skin of your butt' that produce a chronic hormone level rather than the natural ebb and flow of the menstrual cycle. 16. The hosts describe a client with premature ovarian insufficiency (not HA) on consistent daily estrogen and progesterone doses, noting that despite stable protocols, the client periodically shows signs of estrogen dominance — heavy bleeding, breakthrough bleeding, dark brown spotting — correlating with lifestyle changes. 17. Both hosts note that many clients arrive at the HA Society after having been placed on HRT or hormonal protocols that failed to restore ovulation, and that the treatment approaches vary wildly — cycling vs. non-cycling progesterone, patches vs. pills vs. pellets — suggesting the field lacks standardized care. 18. The tone is speculative and explicitly non-dogmatic; the hosts repeatedly disclaim they are not telling listeners what to do and are sharing observations rather than clinical conclusions. 19. Women with HA who are being offered HRT or GLP-1 prescriptions and want a framework for evaluating those options from an HA-specific perspective will find the most value here. 20. Listeners who want direct clinical guidance, peer-reviewed citations, or a neutral presentation of the research will find the format too opinion-driven and anecdote-heavy.

As heard by us

A direct warning about GLP-1s, hormone treatment, and missing periods, grounded in recovery cases.

The episode looks closely at how GLP-1 drugs and hormone treatments may push more people toward chronic energy deficit and HA. It is at its strongest when it stays close to recovery work and the case studies, especially primary amenorrhea, missing periods for years, short-term…

Read the full review in PlayNext →

Why you'd press play

A blunt look at GLP-1s, lost cycles, and the next HA wave.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from The Hypothalamic Amenorrhea Podcast